Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + hypomethylating agents + cytarabine
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
This combination therapy consists of the BCL-2 inhibitor venetoclax, a hypomethylating agent (either azacitidine or decitabine), and low-dose cytarabine. It is being evaluated by The First Affiliated Hospital of Soochow University for the treatment of newly diagnosed, unfit patients with CEBPA-mutated acute myeloid leukemia (AML). Venetoclax works by binding to and inhibiting the anti-apoptotic protein BCL-2, thereby restoring the process of apoptosis in cancer cells. Hypomethylating agents (HMAs) like azacitidine and decitabine function as epigenetic modulators by inhibiting DNA methyltransferase, which leads to the reactivation of tumor suppressor genes. Cytarabine is a pyrimidine analog that interferes with DNA synthesis by inhibiting DNA polymerase. The combination of these agents is intended to provide a synergistic antineoplastic effect in molecularly defined subsets of AML.
- Other names
- venetoclax + HMAs + Low-Dose Cytarabinevenetoclax + azacitidine + cytarabinevenetoclax + decitabine + cytarabine
02
Targets
DNA polymerase familyBCL-2 (BCL-2 family)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on venetoclax + hypomethylating agents + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + hypomethylating agents + cytarabine.